LifeStance Health Group (NASDAQ:LFST) Rating Increased to Buy at The Goldman Sachs Group

LifeStance Health Group (NASDAQ:LFST - Get Free Report) was upgraded by equities researchers at The Goldman Sachs Group from a "neutral" rating to a "buy" rating in a research note issued to investors on Monday, MarketBeat.com reports. The firm presently has a $10.00 price target on the stock. The Goldman Sachs Group's price objective indicates a potential upside of 29.03% from the company's previous close.

Separately, Barclays lifted their target price on shares of LifeStance Health Group from $6.00 to $7.00 and gave the stock an "underweight" rating in a report on Monday, November 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $8.70.

LifeStance Health Group Stock Up 8.1 %

LifeStance Health Group stock traded up $0.58 during trading hours on Monday, hitting $7.75. The stock had a trading volume of 2,211,397 shares, compared to its average volume of 1,524,721. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $2.97 billion, a P/E ratio of -29.50 and a beta of 1.28. LifeStance Health Group has a 12-month low of $4.64 and a 12-month high of $9.20. The stock's 50-day moving average price is $7.17 and its 200-day moving average price is $6.33.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.05. The business had revenue of $312.70 million during the quarter, compared to analysts' expectations of $302.25 million. LifeStance Health Group had a negative net margin of 7.90% and a negative return on equity of 6.66%. The business's revenue for the quarter was up 18.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.17) earnings per share. Equities research analysts anticipate that LifeStance Health Group will post -0.2 EPS for the current fiscal year.

Insider Activity

In other news, Director Robert Bessler sold 75,000 shares of the business's stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $7.54, for a total transaction of $565,500.00. Following the completion of the transaction, the director now directly owns 1,424,447 shares of the company's stock, valued at $10,740,330.38. The trade was a 5.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.60% of the stock is owned by corporate insiders.

Institutional Trading of LifeStance Health Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Townsquare Capital LLC purchased a new stake in LifeStance Health Group during the third quarter valued at approximately $73,000. Park Edge Advisors LLC purchased a new stake in LifeStance Health Group during the third quarter valued at approximately $73,000. CIBC Asset Management Inc purchased a new stake in LifeStance Health Group during the second quarter valued at approximately $53,000. Algert Global LLC purchased a new stake in LifeStance Health Group during the second quarter valued at approximately $57,000. Finally, Victory Capital Management Inc. increased its holdings in LifeStance Health Group by 27.0% during the second quarter. Victory Capital Management Inc. now owns 14,407 shares of the company's stock valued at $71,000 after buying an additional 3,063 shares during the last quarter. 85.50% of the stock is owned by hedge funds and other institutional investors.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.